Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(9 years from now) |
Rhopressa is owned by Alcon Labs Inc.
Rhopressa contains Netarsudil Mesylate.
Rhopressa has a total of 14 drug patents out of which 0 drug patents have expired.
Rhopressa was authorised for market use on 18 December, 2017.
Rhopressa is available in solution/drops;ophthalmic dosage forms.
Rhopressa can be used as reduction of elevated intraocular pressure.
Drug patent challenges can be filed against Rhopressa from 18 December, 2021.
The generics of Rhopressa are possible to be released after 14 March, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC